Zurich Heart
Berlin Science Week 2017
Credit: ETH Zürich / Paper Art: Katrin Rodegast, Picture: Ragnar Schmuck; Stadtplan: Hallwag Kümmerly+Frey AG
"Zurich Heart" is a visionary interdisciplinary flagship project of the University Medicine Zurich (Hochschulmedizin Zürich). The project aims at developing a fully implantable artificial heart. In industrial nations, approximately 1-2% of the population suffers from severe heart failure summing up to 10 million people in Europe. Heart transplantation or the implantation of an artificial heart is the only treatment option for severe heart failure. Nearly 20 research groups of ETH Zurich, the University of Zurich, the German Heart Center Berlin and other partner institutions combine their synergies in a visionary approach to improve the contemporary ventricular assist devices. Innovative components for transcutaneous energy supply, improved surface materials to avoid thromboembolic complications, highly efficient and adaptive regulation and sensor technology as well as soft materials will be the essence of the "Zurich Heart".
Public Conference
Wednesday, 1 November 2017
17.30 - 19.30 h
Door opening time: 17.00 h
Venue
Musikbrauerei, Greifswalder Str. 23A, 10405 Berlin
RSVP
There is no charge to attend this event, however we kindly request that you register external page here.
Programme
Speakers
Moderation: external page David Matthews
Times Higher Education
external page Volkmar Falk
Professor of Cardiovascular Surgery, German Heart Center Berlin
Edoardo Mazza
Professor of Mechanics, ETH Zurich
Laura Bernardi
Institute for Mechanical Systems, ETH Zurich
Marianne Schmid Daners
Institute of Design, Materials and Fabrication, ETH Zurich
external page Panagiotis Pergantis
Department of Cardiothoracic and Vascular Surgery, German Heart Center Berlin
Georgios Stefopoulos
Institute of Energy Technology, ETH Zurich
Bente Thamsen
Institute of Design, Materials and Fabrication, ETH Zurich
external page Lena Wiegmann
Institute of Physiology, University of Zurich
external page Simone Bottan
CEO, HYLOMORPH AG